Kintai Therapeutics launches to tackle the interface between the gut, immune system, and brain
Saturday, April 20, 2019 - 07:00
in Biology & Nature
The start-up, founded by Flagship Pioneering, is developing small-molecule drugs aimed at the gut microbiome, gut immune cells, and enteric nervous system